melanotan-2 is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2025-11-23. Numbers and descriptions here follow the published literature rather than marketing material.
Published pharmacokinetic information is limited and comes mainly from small studies rather than registrational trials. Plasma half-life is usually described as short, on the order of tens of minutes, followed by rapid tissue distribution and clearance of the intact peptide. Metabolites and low concentrations of parent compound have been reported in urine, a detail relevant to anti-doping and forensic testing. Whether repeated exposure changes receptor sensitivity or clearance over time remains an open question. Values differ noticeably between analytical assays, so published numbers should be read as approximate rather than definitive.
Melanotan II is a synthetic cyclic heptapeptide with the sequence Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH2, corresponding to a molecular formula of C50H69N15O9 and a monoisotopic mass near 1024 daltons. It was designed as a structural analogue of alpha-melanocyte-stimulating hormone, a peptide hormone produced by cleavage of proopiomelanocortin. A lactam bridge between the aspartate and lysine side chains closes the ring, and the C-terminal amide removes a free carboxyl group. Both modifications increase resistance to enzymatic degradation compared with the linear parent hormone. Four substitutions distinguish it from afamelanotide, the linear analogue studied under the name melanotan I.
Regulatory status varies by jurisdiction, and the substance is frequently described as unapproved for therapeutic use. Some authorities classify it alongside prescription-only medicines or controlled categories, while others address it through general consumer protection rules. Analytical surveys have reported mismatches between label claims and measured content in products sold online, although the scope of such testing is limited. Whether these discrepancies are widespread remains an open question. Discussion in the literature therefore tends to combine chemistry, supply-chain observation and policy analysis.
The material is commonly handled as a lyophilized powder in sealed vials. The solid dissolves readily in water and in polar organic solvents, producing a clear solution after reconstitution. Light, heat and repeated freeze-thaw cycles are the concerns most often raised in handling guidance, because peptide bonds and the constrained ring can degrade. Working solutions are generally prepared fresh, and material left in solution is treated as less stable than the dry form. These properties shape how laboratories store and aliquot reference material.
Identity and purity are assessed mainly by reversed-phase high-performance liquid chromatography with ultraviolet detection, often paired with mass spectrometry. Retention time supports identity, while the mass spectrum confirms the molecular weight of the intact peptide. Purity is frequently reported as a percentage of total peak area, a figure that depends on the wavelength, column and gradient used. Impurity profiling may also look for truncated sequences, oxidised forms and residual counterions. Amino acid analysis and peptide mapping provide orthogonal confirmation when required.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C50H69N15O9 | Cyclic heptapeptide, C-terminally amidated |
| Approximate molecular mass | 1024 Da | Monoisotopic mass of the free peptide |
| Appearance | White to off-white powder | Typically supplied as a lyophilised solid |
| Solubility class | Soluble in water and polar solvents | Also dissolves in neutral aqueous buffer |
| Common synonyms | Melanotan II, MT-II, MT-2 | Described as a melanocortin agonist in early literature |
Activity is attributed to agonism at melanocortin receptors, particularly MC1R and MC4R. Activation of MC1R on melanocytes increases melanin synthesis, which underlies the reported tanning effect. MC4R engagement in the central nervous system is linked to appetite suppression and to effects on sexual arousal reported in early clinical studies. Those studies were small and were not designed to establish efficacy or long-term safety. Receptor selectivity among the melanocortin subtypes is not absolute, which complicates attribution of any effect to a single pathway.
Regulatory treatment varies between countries. Several national medicines agencies have classified the peptide as unapproved, and customs authorities in some jurisdictions seize shipments on that basis. A few jurisdictions channel supply through prescription-only frameworks that do not list the substance by name. Because the material circulates mainly through online vendors, composition and purity are rarely verified before sale. Surveys of unapproved peptide products have reported labels that did not match measured content in a substantial fraction of samples.
Melanotan II is a synthetic cyclic heptapeptide analogue of alpha-melanocyte-stimulating hormone, a naturally occurring peptide involved in pigmentation signalling. Its structure substitutes a lactam bridge between side chains to increase stability relative to the native hormone. The compound is also known by the shorthand MT-II and by several non-proprietary synonyms used in research catalogues. It is not an approved therapeutic product in any major jurisdiction; material sold under this name is typically offered as a laboratory reagent rather than as a medicine.
Regulatory treatment varies by country. In the United States the peptide is not approved as a medicine, and products offered for human use may be treated as unapproved new drugs; some states also restrict sale. Australia, the United Kingdom, and European Union member states apply comparable restrictions to unapproved peptide products. Border agencies have seized shipments labelled as research chemicals. Classification may change over time, and the legal position for personal importation is not clearly settled in most published guidance.
Lyophilised melanotan-2 is supplied as a solid, which is more stable than a solution. The material is hygroscopic, so weighing is done quickly, in low humidity, with the container kept sealed. Reconstitution usually uses water for injection or bacteriostatic water, added down the wall of the vial to limit foaming. A reconstituted solution is held at 2 to 8 °C and kept away from light. Repeated freezing and thawing of the same vial is avoided because ice crystal formation and concentration effects degrade the peptide.
Melanocortin receptors comprise five subtypes with distinct tissue distributions and functions. Melanotan-2 is described in the literature as a non-selective agonist that engages several of these subtypes, including MC1R, MC3R, MC4R, and MC5R. MC1R is the subtype most directly linked to melanin production in skin cells. Because the compound is not subtype-selective, its observed effects in experimental settings are generally attributed to activity across multiple receptor pathways rather than to a single target.
Melanotan-2 is a synthetic linear peptide built from seven amino acids arranged in a short chain. Its sequence is commonly written as Ac-Nle-Asp-His-D-Phe-Arg-Trp-Lys-NH2, which includes a modified N-terminus and an amidated C-terminus. The molecule belongs to the melanocortin family and acts as a receptor agonist. Structural features such as the D-phenylalanine residue and the Nle substitution are associated with increased stability against enzymatic degradation relative to the natural parent peptide.
== Impact on human pharmaceutical supply == In August 2009 the United States Food and Drug Administration advised pharmaceutical manufacturers that they should determine if they are using components possibly contaminated with melamine and test those components at risk, as well as make sure they get certifications from suppliers that at-risk components have been tested appropriately. A new guidance lists 27 components the agency considers to be at risk of melamine contamination based on its search of U.S. Pharmacopeia/National Formulary monographs and its Inactive Ingredient Database. The list — which includes adenine, ammonium salts, gelatin, guar gum, lactose, povidone and taurine — is not all-inclusive, the guidance says. "For the purpose of this guidance, we use the term at-risk component to mean those ingredients or raw materials that rely on a test for nitrogen content for their identity or purity or strength, and that contain nitrogen in amounts greater than 2.5 percent."
Heseltine asked for his dissent to be minuted, and this was not done, although Cabinet Secretary Robert Armstrong stated that this had been an error and added it himself. On Monday 16 December Heseltine sat on the front bench with obvious disapproval when Brittan told the House that it was up to Westland to decide; on Wednesday 18 December he won the backing of the Commons Defence Committee for the European Consortium. On Thursday 19 December the matter was discussed at Cabinet for ten minutes: Cabinet approved leaving the decision to Westland and Heseltine was ordered to cease campaigning for the European option. Heseltine had failed to drum up enough support among possible allies like Tebbit, Howe, Walker, Norman Fowler and Tom King. A ministerial colleague at the time described him as "absolutely looney, completely hyped up with the thing" and of having a "persecution mania".
== Histidine-specific protein kinases == Histidine kinases (EC 2.7.13.-) are structurally distinct from most other protein kinases and are found mostly in prokaryotes as part of two-component signal transduction mechanisms. A phosphate group from ATP is first added to a histidine residue within the kinase, and later transferred to an aspartate residue on a 'receiver domain' on a different protein, or sometimes on the kinase itself. The aspartyl phosphate residue is then active in signaling. Histidine kinases are found widely in prokaryotes, as well as in plants, fungi and eukaryotes. The pyruvate dehydrogenase family of kinases in animals is structurally related to histidine kinases, but instead phosphorylate serine residues, and probably do not use a phospho-histidine intermediate.
John Neely Kennedy (born November 21, 1951) is an American politician and attorney who has served as the junior United States senator from Louisiana since 2017. A member of the Republican Party, he served as the Louisiana State Treasurer from 2000 to 2017, as Secretary of the Louisiana Department of Revenue from 1996 to 1999, and as special counsel and then cabinet member to Governor Buddy Roemer from 1988 to 1992. Born in Centreville, Mississippi, Kennedy graduated from Vanderbilt University and the University of Virginia School of Law, and earned a law degree from the University of Oxford. In 1988, Governor Buddy Roemer selected Kennedy to serve as special legal counsel and later appointed him Secretary of the Cabinet. He left Roemer's staff in 1991 to run for state attorney general as a Democrat. In 1999, he was elected state treasurer; he was reelected in 2003, 2007, 2011, and 2015. Kennedy ran for U.S. Senate in 2004 and 2008. In August 2007, he became a Republican. In 2016, when U.S. senator David Vitter opted not to seek reelection, Kennedy ran for Senate again. He finished first in the November nonpartisan blanket primary and defeated State Public Service Commissioner Foster Campbell in the December runoff. He was sworn in on January 3, 2017. Kennedy was one of six Republican senators to object to the certification of Arizona's electors in the 2020 presidential election. In 2022, he was reelected to the Senate. Kennedy is set to be Louisiana's senior senator when Bill Cassidy leaves office in 2027.
== Further reading == Havelock, H. (April 1898). "The Cossacks in the Early Seventeenth Century". English Historical Review. 13 (50): 242–260. JSTOR 547225. Longworth, Philip (1969). The Cossacks. London: Constable. Seaton, Albert (1985). The Horsemen of the Steppes: The Story of the Cossacks. London: The Bodley Head. ISBN 978-0-370-30534-9. Summerfield, Stephen (2005). Cossack Hurrah: Russian Irregular Cavalry Organisation and Uniforms during the Napoleonic Wars. Partizan Press. ISBN 978-1-85818-513-2. Summerfield, Stephen (2007). The Brazen Cross: Brazen Cross of Courage: Russian Opochenie, Partizans and Russo-German Legion during the Napoleonic Wars. Partizan Press. ISBN 978-1-85818-555-2. Ure, John (1999). The Cossacks. London: Constable. ISBN 978-0-094-77400-1. Witzenrath, Christoph (2007). Cossacks and the Russian Empire, 1598–1725: Manipulation, Rebellion and Expansion into Siberia. Routledge. ISBN 978-1-134-11749-9. "General der Flieger Hellmuth Felmy" [The Cossack Corps]. US Army Historical Division. Hailer Publishing. 2007. Archived from the original on 2009-04-15. Kondufor, Yuri (1986). A Short History of the Ukraine. Kyiv: Naukova Dumka.
Sources: en.wikipedia.org
Gustavo Bounous was a research medical doctor. He was born in Luserna, Italy on July 10, 1928. He was educated at the University of Turin and at the University of Genoa. Then, he worked as a research fellow in surgery at the Indiana Medical Center. In 1963 he moved to Canada. He became a professor of surgery, successively at the Université de Sherbrooke, 1973–1985, after that, at McGill University, 1985–1993. He died at the age of 83 on December 29, 2011.
== Bacteriophage T4 DNA polymerase == Bacteriophage (phage) T4 gene 43 encodes the phage's DNA polymerase replicative enzyme. Temperature-sensitive (ts) gene 43 mutants have been identified that have an antimutator phenotype, that is a lower rate of spontaneous mutation than wild type. Studies of one of these mutants, tsB120, showed that the DNA polymerase specified by this mutant copies DNA templates at a slower rate than the wild-type polymerase. However, the 3' to 5' exonuclease activity was no higher than wild-type. During DNA replication the ratio of nucleotides turned over to those stably incorporated into newly formed DNA is 10 to 100 times higher in the case of the tsB120 mutant than in wild-type. It was proposed that the antimutator effect may be explained by both greater accuracy in nucleotide selection and an increased efficiency of removal of noncomplementary nucleotides (proofreading) by the tsB120 polymerase. When phage T4 virions with a wild-type gene 43 DNA polymerase are exposed to either ultraviolet light, which introduces cyclobutane pyrimidine dimer damages in DNA, or psoralen-plus-light, which introduces pyrimidine adducts, the rate of mutation increases. However, these mutagenic effects are inhibited when the phage's DNA synthesis is catalyzed by the tsCB120 antimutator polymerase, or another antimutator polymerase, tsCB87. These findings indicate that the level of induction of mutations by DNA damage can be strongly influenced by the gene 43 DNA polymerase proofreading function.
=== Development === The series originated from discussions between Toho producers and Yeon Sang-ho in 2018, during which Yeon selected The Human Vapor from Toho's "Transforming Human Series" for its blend of speculative science and human drama. Yeon, known for global hits like Train to Busan (2016) and Netflix's Hellbound (2021), emphasized the original film's "skillful sci-fi expressions" and emotional core, stating: "While it is a sci-fi thriller, at its core, it is a story about people. We focused on treating human emotions with care and portraying the characters’ humanity." Script development took three years, with Ryu Yong-jae—Yeon's collaborator on Parasyte: The Grey (2024)—joining as co-writer. Shinzo Katayama, who was acclaimed for his directing live action TV seriesGannibal (2022), was selected as director for his ability to merge genre elements with intimate storytelling. Katayama, upon revisiting the original, noted: "I was intrigued by its blend of human drama and romantic elements, despite featuring an absurd creature like the Human Vapor." The project represents Netflix's first partnership with Toho, aiming to revive the studio's tokusatsu legacy for global audiences using cutting-edge VFX. Wow Point, the production company behind Parasyte: The Grey, co-produces, infusing Korean expertise in genre storytelling.
The composition-gradient, multi-angle static light scattering (CG-MALS) measurement mixes a series of aliquots of different concentrations or compositions, measures the effect of the changes in light scattering as a result of the interaction, and fits the correlated light scattering changes with concentration to a series of association models in order to find the best-fit descriptor. Weak, non-specific interactions are typically characterized via the second virial coefficient. For specific binding, this type of analysis can determine the stoichiometry and equilibrium association constant(s) of one or more associated complexes, including challenging systems such as those that exhibit simultaneous homo- and hetero-association, multi-valent interactions and cooperativity. Dynamic light scattering (DLS), also known as quasielastic light scattering (QELS), or photon correlation spectroscopy, processes the time-dependent fluctuations in scattered light intensity to yield the hydrodynamic radius of particles in solution. The hydrodynamic radius is the radius of a solid sphere with the same translational diffusion coefficient as that measured for the sample particle. As proteins associate, the average hydrodynamic radius of the solution increases. Application of the Method of Continuous Variation, otherwise known as the Job plot, with the solution hydrodynamic radius as the observable, enables in vitro determination of Kd, complex stoichiometry, complex hydrodynamic radius, and the ΔH° and ΔS° of protein–protein interactions.
Sources: en.wikipedia.org
=== Tracking of Cell Movement in Developmental Biology === EosFP has been used to track cell movements during embryonic development of Xenopus laevis. At the two-cell/ early gastrula stage, capped mRNA coding for a dimeric EosFP (d2EosFP) was injected into cells and locally photoconverted using fluorescence microscopy. These fluorescent embryos demonstrated the dynamics of cell movement during neurulation. EosFP was found in part of the notochord which shows the possibility of EosFP to be used in fate-mapping experiments.
==== Background ==== In spring 1985 Heseltine displayed little interest in Westland helicopters when approached by Tebbit (then Secretary of State for Trade and Industry) at the time of Alan Bristow's bid for the company, as plenty of American helicopters were available to meet Britain's defence requirements. He attended two meetings about the company's future in June 1985, chaired by Thatcher. Heseltine, who had a poor opinion of Westland's management, was willing to inject £30 million, provided the Treasury contributed half. The idea was not approved. Heseltine took against the new chairman Sir John Cuckney's plan that Westland merge with United Technologies Corporation, of which the US company Sikorsky was a subsidiary, after realising that Westland would probably become responsible for assembling the Sikorsky UH-60 Black Hawk helicopter, which the Ministry of Defence would then be under great pressure to buy, whereas he preferred Westland to go into receivership so that GEC and British Aerospace could buy the viable parts of the business. In mid-October Heseltine suggested a European consortium (which would include French Aérospatiale, German MBB and Italian Agusta). The new Trade and Industry Secretary Leon Brittan at first urged Thatcher to consider a European option (Heseltine later said Brittan preferred this option, although Brittan denied this). The Government was officially neutral (i.e. arguing that it was a matter for Westland directors and shareholders) but by November Heseltine was pushing the European option hard.
== Research == Bridging the fields of chemical engineering, biochemistry, and biomaterials, Palmer's research focuses on the biophysical properties of hemoglobin, blood and plasma substitutes, and novel methods in protein purification, including interactions between adjacent cells Palmer currently holds several patents on his work.
=== Laboratory synthesis === The chemical synthesis of DMT has been described. It can be synthesized through several possible pathways from different starting materials. The two most commonly encountered synthetic routes are through the reaction of indole with oxalyl chloride followed by reaction with dimethylamine and reduction of the carbonyl functionalities with lithium aluminium hydride to form DMT. The second commonly encountered route is through the N,N-dimethylation of tryptamine using formaldehyde followed by reduction with sodium cyanoborohydride or sodium triacetoxyborohydride. Sodium borohydride can be used but requires a larger excess of reagents and lower temperatures due to it having a higher selectivity for carbonyl groups as opposed to imines. Procedures using sodium cyanoborohydride and sodium triacetoxyborohydride (presumably created in situ from cyanoborohydride though this may not be the case due to the presence of water or methanol) also result in the creation of cyanated tryptamine and beta-carboline byproducts of unknown toxicity while using sodium borohydride in absence of acid does not. Bufotenine, a plant extract, can also be synthesized into DMT. Alternatively, an excess of methyl iodide or methyl p-toluenesulfonate and sodium carbonate can be used to over-methylate tryptamine, resulting in the creation of a quaternary ammonium salt, which is then dequaternized (demethylated) in ethanolamine to yield DMT. The same two-step procedure is used to synthesize other N,N-dimethylated compounds, such as 5-MeO-DMT.
Through discretionary grants, federal agencies set program objectives, eligibility criteria, and funding conditions in Notices of Funding Opportunity (NOFOs), which can shape how artificial intelligence technologies are developed and deployed by funding recipients. Guidance issued by the Office of Management and Budget (OMB) to implement the Executive Order's policies applied risk-management requirements primarily to procurement and agency uses of AI, while generally excluding federal financial assistance programs. In April 2024, the Federal Trade Commission (FTC) announced Operation AI Comply, a cross-agency initiative to ensure that AI products and marketing claims comply with existing consumer-protection, fair-credit, and truth-in-advertising laws. The FTC stated that companies deploying AI systems must "keep their AI claims in check" and warned that false or misleading representations about AI capabilities would be subject to enforcement under the FTC Act. In 2024, a bipartisan House task force released a report on artificial intelligence, while representatives Jay Obernolte and Lori Trahan subsequently developed a bipartisan proposal concerning AI regulation.
Sources: en.wikipedia.org
No. It is a synthetic analogue carrying four amino acid changes, a lactam ring and an amidated C-terminus. The natural hormone is a linear thirteen-amino-acid peptide processed from proopiomelanocortin.
Afamelanotide is the linear analogue [Nle4-D-Phe7]-alpha-MSH, sometimes called melanotan I, while melanotan II is cyclic and carries three further substitutions. The two are distinct molecules and are not interchangeable in analytical testing.
Binding to the four melanocortin receptor subtypes is well documented in vitro. The relative contribution of each subtype to whole-body effects in humans is far less certain.
The dry powder is more stable during transport and storage than a solution. It also allows a known amount of material to be reconstituted at a chosen concentration.